Group B - The World Congress On Controversies in Urology (CURy)

The 2nd World Congress on

Controversies in Urology (CURy)

Lisbon, Portugal, February 5- 8, 2009

Group B

Saturday, February 7, 2009

Board	Topic: Nephrolithiasis
75	UVA URSI FOR PREVENTION OF URINARY TRACT INFECTION IN ESWL TREATMENT D. Durovic, P. Dragoljub, D. Nale, D. Djordjevic Department of Urology, Clinical Center of Montenegro, Podgorica Montenegro
76	IS TUBELESS PERCUTANEOUS NEPHROLITHOTOMY (PCNL) HERE TO STAY? A 2 YEAR SINGLE CENTRE EXPERIENCE I. El-Mokadem, T. Page, P. Menezes, P. English, R. Marsh, P. Johnson Urology Department & Radiology Department, Sunderland Royal Hospital, Sunderland, UK
77	NON-LITHIASIC ACUTE RENAL PAIN: COMPUTERIZED TOMOGRAPHY EVALUATION P. Eufrasio, M. Seco, B. Parada, A. Mota Department Urology Renal Transplant, Hospitals of the University of Coimbra, Coimbra, Portugal
78	URETEROSCOPIC TREATMENT OF LARGE RENAL CALCULI (2 TO 4CM) N. Leone, S. Hubosky, A. Mariani, D. Bagley Thomas Jefferson University Hospital, Ardmore, USA
79	COMPLICATIONS AFTER 5.000 RETROGRADE URETEROSCOPIES: A SINGLE-CENTRE EXPERIENCE P. Geavlete, D. Georgescu, R. Multescu, B. Geavlete Department of Urology, "Saint John" Emergency Clinical Hospital, Bucharest, Romania
80	PCNL COMPLICATIONS AFTER 2,000 PROCEDURES P. Geavlete, V. Cauni, V. Mirciulescu, D. Georgescu, R. Multescu, B. Geavlete Department of Urology, "Saint John" Emergency Clinical Hospital, Bucharest, Romania
81	DOUBLE J INDWELLING – EXPERIENCE ON 10,000 PROCEDURES P. Geavlete, V. Mirciulescu, D. Georgescu, R. Multescu, B. Geavlete Department of Urology, "Saint John" Emergency Clinical Hospital, Bucharest, Romania
82	THE EFFECTS OF TOLTERODINE EXTENDED RELEASE AND ALFUZOSIN FOR THE TREATMENT OF DOUBLE-J STENT-RELATED SYMPTOMS S.C. Park, H.J. Jeong, I.Y. Seo, J.S. Rim Wonkwang University School of Medicine and Hospital, Iksan, Korea
83	EFFICIENCY AND SAFETY OF ESWL TREATMENT WITH AND WITHOUT DOUBLE-J STENT FOR KIDNEY STONES 10 TO 20 MM D. Perovic, P. Kavaric, D. Durovic, V. Brajovic Department of Urology, Clinical Center of Montenegro, Podgorica, Montenegro
84	CHANGES OF PLASMA BETA-ENDORPHIN AND ADRENOCORTICOTROPHIC HORMONE LEVELS DURING EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY TREATMENT-RELEVANCE TO PAIN M. Sunay, A. Karabulut, L. Emir, D. Erol 1st Clinic of Urology, Ministry of Health Ankara Teaching and Research Hospital, Ankara, Turkey
85	MANAGEMENT OF PROXIMAL URETERAL CALCULI BIGGER THAN 10 MM: COMPARISION OF SWL, SEMIRIGID AND FLEXIBLE URETEROSCOPY F. Yencilek, K. Sarýca, C. Goktas, O. Canguven, S. Albayrak Department of Urology Yeditepe University Medical Faculty, Istanbul, Turkey

Topic: Overactive Bladder
86	ANALYSIS OF FACTORS AFFECTING RE-TREATMENT AFTER COMPLETION OF INITIAL 12-WEEK TREATMENT WITH TOLTERODINE ALONE IN FEMALE PATIENTS WITH OVERACTIVE BLADDER SYMPTOMS Y.B. Jeong, H.K. Oh, M.W. Cheon, M.K. Kim, J.K. Park, H.J. Kim, Y.G. Kim Chonbuk National University Medical School, Jeonju, Korea
87	LONG-TERM URODYNAMIC EFFECTS OF PERCUTANEOUS POSTERIOR TIBIAL NERVE STIMULATION ON NEUROGENIC DETRUSOR OVERACTIVITY IN PATIENTS WITH MULTIPLE SCLEROSIS S. Kabay, S.C. Kabay, M. Yucel, H. Ozden, Z. Yilmaz Dumlupinar University, Kutahya, Turkey
88	CYTOKINES IN URINE INDICATES URETHRAL ORIGIN OF URGENCY IN THE “OVERACTIVE BLADDER SYNDROME”. O. Lofgren Gynhalsan, Trelleborg, Sweden
89	PROSTAGLANDIN E2 RELEASE BY THE BLADDER UROTHELIUM IS DICTATED BY A COMPLEX INTERACTION OF PHYSIOLOGICAL MEDIATORS; A ROLE IN SENSORY PROCESSING C. Nile, J. de Vente, G. van Koeveringe, J. Gillespie Newcastle University, Newcastle, UK
90	INTRA-TRIGONAL INJECTION OF BOTULINUM TOXIN A IN PATIENTS WITH BLADDER PAIN SYNDROME: RESULTS AT 6-MONTHS OF FOLLOW-UP R. Pinto, A. Silva, T. Lopes, J. Silva, C. Silva, P. Dinis Department of Urology - Hospital de S. Joao, Porto, Portugal
91	EFFECT OF SUB-THALAMIC STIMULATION IN LOWER URINARY TRACT SYMPTOMS R. Pinto, R. Oliveira, A. Silva, J. Silva, C. Silva, M. Guimaraes, M. Rosas, R. Vaz, F. Cruz Department of Urology, Hospital de S. Joao, Porto, Portugal
92	EFFECT OF THE ORAL TRPV1 ANTAGONIST GRC 6211 ON BLADDER REFLEX ACTIVITY OF CHRONIC SPINALIZED RATS A. Silva, C. da Cruz, A. Charrua, R. Pinto, J. Silva, C. Silva, P. Dinis, F. Cruz Department of Urology, Hospital de S.João, Alameda Prof. Hernani Monteiro, Porto, Portugal
93	DO PATIENTS’ PERCEPTIONS AND ATTITUDES TOWARDS TREATMENT OF OAB INFLUENCE COMPLIANCE WITH TREATMENT? J.-J. Wyndaele, G. Schaer, S. Al-Shukri, G. Notarianni, G. Compion Department of Urology, University Hospital Antwerp, Antwerp, Belgium

Topic: Prostate Cancer
94	MONITORING PROSTATE CANCER: THE SPANISH EXPERIENCE A. Alcaraz, F.J. Burgos, J.M. Cozar, F. Gomez-Veiga, J. Morote, E. Solsona, M. Unda, J. Carballido Hospital Clinic (IDIBAPS), Barcelona, Spain
95	DOES INFLAMMATION ON PROSTATE NEEDLE BIOPSY INCREASE THE LIKELIHOOD OF CANCER ON SUBSEQUENT BIOPSY? COMPARATIVE STUDY ABOUT 100 CASES S. Ben Rhouma, S. Sallami, M. Chelif, M. Tanguour, K. Cherif, S. Rebai, N.E. Kchir, Y. Nouira, N. Berrais, A. Horchani Department of Urology & Pathology, La Rabta Hospital-University, Tunis, Tunisia
96	GLOBAL DISCREPANCIES IN PROSTATE CANCER MANAGEMENT: HOW CAN WE BRIDGE THE GAP? J.R. Bhatt, R.P. MacDonagh Northampton General Hospital NHS Trust, Northampton, UK
97	INCIDENCE OF ADENOCARCINOMA OF THE PROSTATE AFTER PHOTOSELECTIVE VAPORIZATION OF THE PROSTATE FOR PROSTATE ENLARGEMENT G. Bonkat, M. Rieken, C.A. Rentsch, S. Wyler, T. Gasser, A. Bachmann University Hospital Basel, Department of Urology, Basel, Switzerland
98	OPEN VERSUS ROBOTIC RADICAL PROSTATECTOMY IN THE PATIENTS WITH A HISTORY OF PRIOR TURP: SINGLE SURGEON’S EXPERIENCE Y.D. Choi, W.S. Ham, W.T. Kim, H.J. Jung, J.S. Lee Department of Urology, Yonsei University, Seoul, South Korea
99	ANALYSIS OF RELATIONSHIP BETWEEN PROSTATE VOLUME AND GLEASON SCORE IN PROSTATE CANCER Y.D. Choi, W.S. Ham, W.T. Kim, K.H. Kim, H.J. Ju Department of Urology, Yonsei University, Seoul, South Korea
100	CHEMICAL CASTRATION WITH INTRATESTICULAR INJECTION OF 20% HYPERTONIC SALINE: A MINIMALLY INVASIVE METHOD M. Dadal, M. Sunay, L. Emir, D. Erol 1st Clinic of Urology, Ministry of Health Ankara Teaching and Research Hospital, Ankara, Turkey
101	CLINICAL OUTCOME OF HIGH RISK PROSTATE ADENOCARCINOMA (T3 AND GLEASON SCORE > OR = 8) L. Emir, M. Sunay, M. Dadal, D. Erol 1st Clinic of Urology, Ministry of Health Ankara Teaching and Research Hospital, Ankara, Turkey
102	OBESITY, TESTOSTERONE AND PROSTATE CANCER P. Eufrasio, B. Parada, R. Patrao, F. Rolo, A. Mota Department Urology Renal Transplant, Hospitals of the University of Coimbra, Coimbra, Portugal
103	IMPROVED PREDICTION OF RADICAL PROSTATECTOMY PATHOLOGICAL OUTCOMES USING A PANEL OF PROSTATE CANCER BIOMARKERS D.M. Fanning, Y. Fan, L. Sullivan, M. Burke, T. Lynch, H. Klocker, W. Horninger, J.M. Fitzpatrick, R.W.G. Watson Conway Institute of Biomolecular and Biomedical Research, School of Medicine and Medical Science, University College & Department of Urology, St. James's Hospital, Dublin, Ireland
104	FUNCTIONAL GENETIC POLYMORPHISM IN THE HYPOXIA INDUCIBLE FACTOR 1 ALPHA AND PROSTATE CANCER A. Fraga, R. Ribeiro, F. Pina, C. Silva, F. Lobo, R. Medeiros Urology Department, D Pedro V Military Hospital, Lisbon Medical Centre & Portuguese Institue of Oncology, Porto, Portugal
105	CIGARETTE SMOKING AND ALCOHOL INTAKE INCREASE OXIDATIVE STRESS IN PROSTATE CANCER PATIENTS M.O. Freitas, C. Rabaça, I. Baldeiras, T. Proença, R. Pascoal, F. Valido, A. Mota-Pinto, A. Sarmento-Ribeiro General Pathology Institute, Faculty of Medicine, University of Coimbra, Portugal
106	CRYOSURGERY WITH SHORT TERM NEOADJUVANT ANDROGEN ABLATION AS PRIMARY TREATMENT FOR LOCALIZED PROSTATE CANCER A. Galosi, V. Lacetera, L. Gasparri, M. Tiroli, G. D'Anzeo, L. Franco, G. Muzzonigro Department of Urology, Azienda Ospedali Riuniti, Ancona, Italy
107	ZD4054, A SPECIFIC ENDOTHELIN-A RECEPTOR ANTAGONIST WITH POTENTIAL FOR THE TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER J. Growcott, N.A. Dawson, T. Morris, D. Phung, N.D. James AstraZeneca, Alderley Park, Macclesfield, UK
108	UPGRADING AND UPSTAGING OF BIOPSY GLEASON 6 PROSTATE CANCER J.H. Hong, C.-S. Kim, H. Ahn, M.K. Jo, H.G. Kim, S.I. Seo, K.-S. Lee Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
109	IMPACT OF PRETREATMENT FACTORS, BIOPSY GLEASON GRADE VOLUME INDEX AND POST TREATMENT NADIR PSA ON CAUSE-SPECIFIC AND OVERALL SURVIVAL IN PATIENTS WITH STAGE IV PROSTATE CANCER K. Ito, S. Miyamoto, T.Yamamoto, K. Suzuki, K. Suzuki, H. Yamanaka Department of Urology, Gunma University Graduate School of Medicine, Maebashi Japan
110	PHASE III TRIAL OF DEGARELIX VS LEUPROLIDE: COMPARING SAFETY AND TOLERABILITY P. Iversen, J.K. Jensen, T.K. Olesen, B.-E. Persson Department of Urology, University of Copenhagen, Copenhagen, Denmark
111	DEGARELIX COMPARED WITH LEUPROLIDE IN A 12-MONTH RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, PHASE III STUDY (CS21) IN PROSTATE CANCER (PCA) PATIENTS P. Iversen, J.K. Jensen, T.K. Olesen, B.-E. Persson Ferring Pharmaceuticals & Department of Urology, University of Copenhagen, Copenhagen, Denmark
112	THE VALUE OF THE PROSTATE BIOPSY TO DIAGNOSE THE PROSTATE CANCER IN THE PATIENTS WITH HIGH PSA Y.-S. Kim, H.-J. Jung, J.-H. Lee, K.-K. Park NHIC Ilsan Hospital, Koyang, Korea
113	A PROSPECTIVE COMPARISON STUDY OF FLUORINE 18-FLUORODEOXYGLUCOSE PET/CT AND CARBON 11-ACETATE PET/CT FOR THE LOCALIZATION OF PROSTATE CANCER: K.H. Lee, J.Y. Joung, K.S. Han, K.S. Cho, S.K. Kim, W.S. Park Urologic Oncology Clinic, Jungbalsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea
114	A PROSPECTIVE STUDY OF EGFR AS PREDICTING FACTOR ON BIOCHEMICAL RECURRENCE AFTER RRP K.H. Lee, J.Y. Joung, K.S. Han, K.S. Jo, H.K. Seo, J.S. Chung, W.S. Park, J.W. Lee National Cancer Center, Goyang, Korea
115	PREDICTION OF GLEASON SCORE UPGRADING IN LOW RISK PROSTATE CANCERS DIAGNOSED VIA MULTI (¡ 12)-CORE PROSTATE BIOPSY S.E. Lee, S.J. Jeong, S.-S. Byun, S.K. Hong Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea
116	PREDICTION OF PATHOLOGIC TUMOR BILATERALITY IN UNILATERAL, LOW RISK PROSTATE CANCERS DIAGNOSED VIA MULTICORE PROSTATE BIOPSY S.E. Lee, S.J. Jeong, S.-S. Byun, S.K. Hong Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea
117	THE ROLE OF FAS/FASL APOPTOTIC SYSTEM IN PROSTATE CANCER HORMONE-RESISTANCE L. Lima, A.M. Gomes, R. Ribeiro, A. Fraga, F. Pina, F. Lobo, F. Calais-da-Silva, R. Medeiros Molecular Oncology Group - IPO-Porto, Porto, Portugal
118	SALVAGE THERAPY USING HIGH INTENSITY FOCUSED ULTRASOUND FOR LOCAL RECURRENCE OF PROSTATE CANCER AFTER RADIATION THERAPY. S. Mallick, L. Taksin, S. Le Toquin-Bernard, O. Frachet, H. Bensadoun CHU Urology, CHU Cote de Nacre, Caen, France
119	EFFICACY AND SAFETY OF TRANS-RECTAL HIGH INTENSITY FOCUSED ULTRASOUND IN THE TREATMENT OF LOCALIZED PROSTATE CANCER S. Mallick, L. Taksin, S. Le Toquin-Bernard, O. Frachet, H. Bensadoun CHU Urology, CHU Cote de Nacre, Caen, France
120	CORRELATION BETWEEN PROSTATE SATURATION BIOPSIES AND RADICAL PROSTATECTOMY SPECIMENS: CAN WE PREDICT THE FINAL PATHOLOGICAL OUTCOME? S. Mallick, F. Comoz, S. Le Toquin-Bernard, O. Frachet, C. Jeanne- Pasquier, P. Rousselot, H. Bensadoun CHU Urology, CHU Cote de Nacre, Caen, France
121	SERUM PSA IN COMBINATION WITH SEMINAL IL-6: PREDICTIVE VALUE FOR ASYMPTOMATIC INFLAMMATORY PROSTATITIS R. Mandar, P. Korrovits, K. Ausmees, M. Punab Andrology Centre, Tartu University Hospital, Tartu, Estonia
122	IODINE-125 BRACHYTHERAPY (BT) WITH OR WITHOUT EXTERNAL BEAM RADIATION THERAPY (EBRT) FOR HIGH RISK PROSTATE CANCER K. Miki, M. Aoki, S. Egawa Jikei University, Tokyo Japan
123	ONE-STOP PROSTATE CANCER ASSESSMENT CLINIC: CLERICAL OR CLINICAL? A. Mohammed, I. Shergill, S. Gujral, M. Vandal The Ayr Hospital, Ayr, UK
124	RANDOM PSA TESTING – BOON OR BANE? – A 3 YEAR UK EXPERIENCE A. Muneer, A. Blacklock Department of Urology, University Hospitals of Coventry & Warwickshire (UHCW), Coventry, UK
125	CONTROVERSIES IN METASTATIC PROSTATE CANCER TREATMENT B. Pajovic, N. Radojevic, M. Radovic, D. Mandic Forensic Medicine Department, Clinical Center of Montenegro, Podgorica, Montenegro
126	THE INCIDENCE OF ATYPICAL SMALL ACINAR PROLIFERATION (ASAP) AND ITS RISK OF PROSTATE CANCER J.W. Park, W. Kim, B.C. Jeong, S.I. Seo, S.S. Jeon, H.M. Lee, H.Y. Choi Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
127	GLEASON SCORE ON BIOPSY vs RADICAL PROSTATECTOMY - RESULTS OF A CONTEMPORARY SERIES R.F. Patrao, P.T. Nunes, P. Eufrasio, A.J. Roseiro, A.J. Mota Hospitals of the University of Coimbra, Coimbra, Portugal
128	TWO YEARS BIOCHEMICAL FAILURE FREE SURVIVAL FOLLOWING HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) FOR LOCALIZED PROSTATE CANCER: PROSPECTIVE SINGLE CENTER STUDY OF 197 PATIENTS J. Pinthus, F. Farrokhyar, M. Hassouna, E. Woods, W. Orovan The Department of Surgery, McMaster University, Hamilton Ontario, Canada
129	REVISITING THE RELEVANCE OF SURGICAL CASTRATION IN THE MANAGEMENT OF ADVANCED PROSTATE CANCER: WOULD SPEED AND ECONOMY SWAY THE DEBATE? R. Rajasundaram, N. George Urology Department, Royal Preston Hospital, Preston, UK
130	A COMPARISON OF THE INCIDENCE AND LOCATION OF POSITIVE SURGICAL MARGINS IN LAPAROSCOPIC RADICAL PROSTATECTOMY AND RETROPUBIC RADICAL PROSTATECTOMY E.A. Rijo Mora, A. Francés, J. Lorente, Ó. Bielsa, L. Fumadó, J. Lloreta, O. Arango Tora Department of Urology & Department of Pathology, Hospital del Mar, Barcelona, Spain
131	CURRENT OPINION ON CRITERIA FOR LYMPHADENECTOMY IN LOCALISED PROSTATE CANCER W. Runneboom, P. Braam, M. Nanlohy, W. Levens, L. Fossion Department of Urology, Maxima Medical Center, Veldhoven, Netherlands
132	CELL ADHESION MOLECULES IN PROSTATIC CANCER: BASIS OF TUMORARCHITECTURE AND GLEASON GRADING P.E. Stoemmer, P. Torres-Galea Forschungslabor Pathologie, Augsburg, Germany
133	ANTI-CANCER CHEMOTHERAPY GIVEN AFTER PERINEURIAL REPAIR OF INADVERTENTLY INJURED OBTURATOR NERVE HAS NO NEGATIVE EFFECT ON HEALING PROCESS OF INJURED NERVE: A CASE REPORT M. Sunay, A. Karabulut, L. Emir, M. Dadal‎, D. Erol 1st Clinic of Urology, Ministry of Health Ankara Teaching and Research Hospital, Ankara, Turkey
134	EFFECTS OF ANDROGEN AND VALPROIC ACID TREATMENT ON ANDROGEN-DEPENDENT CELL LINE (LNCAP-SF) A. Valentini, F. Conforti, V. Tassone, R. Miano, G. Federici, G. Vespasiani, S. Bernardini U.O.C. Molecular Clinical Biology, Hospital University “Tor Vergata”, Rome, Italy
135	PATHOLOGICAL ASSOCIATION BETWEEN BIOPSY AND SURGICAL SPECIMENS OF PATIENTS WHO WERE DETECTED CARCINOMA IN ONLY ONE CORE BY PROSTATE NEEDLE BIOPSY T. Yamamoto, K. Tashiro, Y. Yamaguchi, K. Hata, H. Sasaki, J. Miki, T. Kimura, A. Furuta, K. Miki, N. Furuta, H. Takahashi, S. Egawa Jikei University School of Medicine, Tokyo, Japan
136	PERINEURAL INVASION AND EFFECT OF RADIOTHERAPY AFTER RADICAL PROSTATECTOMY IN PT2C STAGE PROSTATE CANCER M. Zharkovski, M.M. Marjamigi Department of Urology and Kidney Transplantation, Department of Clinical Oncology, Tartu University Hospital, Tartu, Estonia
137	THE RATE OF INCIDENTAL PROSTATE CANCER IN PATIENTS WHO UNDERWENT RADICAL CYSTOPROSTATECTOMY AND ITS CLINICAL SIGNIFICANCE M. Sunay, L. Emir, M. Dadal‎, D. Erol 1st Clinic of Urology, Ministry of Health Ankara Teaching and Research Hospital, Ankara, Turkey

Topic: TCC / Ureteroscopy
138	URETEROSCOPIC TREATMENT OF UPPER URINARY TCC D. Bagley, N. Leone, S. Hubosky Thomas Jefferson University Hospital, Philadelphia, USA

Topic: Testis Cancer
139	13,17-BIS (1-CARBOXYPROPIONYL) CARBAMOYLETHYL-3,8-BIS (1-DECANYLOXYETHYL)-2,7,12,18-TETRAMETHYL -PORPHYRINATO GALLIUM (III) TO THE TESTICULAR TUMOR AND OTHER CELLS H. Kamano, I. Sakata Kagawa University, Takamatsu, Japan

Late arrivals Topic: Prostate Cancer
140	BIOCHEMICAL DISEASE-FREE SURVIVAL AFTER RADICAL PROSTATECTOMY IN INITIAL PSA> 20 NG/ML PROSTATE CANCER PATIENTS M. Del Canto, J. Lorente, E.A. Rijo Mora, O. Bielsa, L. Fumadó, A. Francés, O. Arango Department of Urology, Hospital del Mar, Barcelona Spain
141	PROGNOSTIC ROLE OF SOMATOSTATIN RECEPTOR SUBTYPES IN HUMAN PROSTATE CANCER A. Gernone, V. Pagliarulo, M. Battaglia Unit of Medical Oncology, Bari, Italy
142	THE FACTOR AFFECTING RADICAL RETROPUBIC PROSTATECTOMY : BONY PELVIC SHAPE IMAGED BY MAGNETIC RESONANCE D. Kwon, S.B. Ryu, K. Park, S.I. Jung, S.O. Kim, K.J. Oh, C.M. Im, J.S. Joo, C.W. Yun, G.P. Kim, J.H. Noh, E.T. Kim Chonnam National Unversity Hwasun Hospital, Gwangju, South Korea
143	THREE MONTHS INTERMITTENT HORMONE THERAPY +/- 5 ALPHA REDUCTASE AS AN ALTERNATE TO ACTIVE MONITORING TO SEPARATE LATENT FROM CLINICALLY SIGNIFICANT PROSTATE CANCER T.Oliver, B. Leibowitz, G. Shaw Barts and London NHS Trust, London, UK
144	COLOR DOPPLER AND MICROBUBBLE CONTRAST AGENT DO NOT IMPROVE THE CANCER DETECTION RATE IN TRANS-RECTAL PROSTATE BIOPTIC SAMPLING G. Taverna, M. Seveso, F. Grizzi, A. Piccinelli, G. Giusti, P. Graziotti Department of Urology, Istituto Clinico Humanitas, Milan, Italy
145	FLUCTUATING PROSTATE-SPECIFIC ANTIGEN DO NOT DECREASE THE RISK OF PROSTATE CANCER G. Taverna, M. Seveso, F. Grizzi, A. Benetti, P. Graziotti Department of Urology, Istituto Clinico Humanitas, Milan, Italy